Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells by Chuang, Jiin-Haur et al.
RESEARCH Open Access
Differential toll-like receptor 3 (TLR3) expression
and apoptotic response to TLR3 agonist in
human neuroblastoma cells
Jiin-Haur Chuang
1,2, Hui-Ching Chuang
2,3, Chao-Cheng Huang
4, Chia-Ling Wu
1, Yung-Ying Du
1, Mei-Lang Kung
5,
Chih-Hao Chen
6, San-Cher Chen
7 and Ming-Hong Tai
5,7*
Abstract
Background: Toll-like receptor-3 (TLR-3) is a critical component of innate immune system against dsRNA viruses
and is expressed in the central nervous system. However, it remains unknown whether TLR3 may serve as a
therapeutic target in human neuroblastoma (NB).
Methods: TLR3 expression in human NB samples was examined by immunohistochemical analysis. Quantitative RT-
PCR and western blot was used to determine TLR3 expression in three human NB cell lines. The effect of TLR3
agonist, polyinosinic-polycytidylic acid (poly(I:C)), on the growth of human NB cells was evaluated by WST-1 cell
proliferation assay, flow cytometry analysis, and immunoblot analysis. Blockade of TLR3 signaling was achieved
using TLR3 neutralizing antibody, small interference RNA, and 2-aminopurine (2-AP), an inhibitor of protein kinase R
(PKR), an interferon-induced, double-stranded RNA-activated protein kinase.
Results: In immunohistochemical studies, TLR3 mainly expressed in the cytoplasm of ganglion cells and in some
neuroblastic cells, but not in the stromal cells in human NB tissues. Among three human NB cell lines analyzed,
TLR3 was significantly up-regulated in SK-N-AS cells at mRNA and protein level compared with other two low
TLR3- expressing NB cells. Treatment with poly(I:C) elicited significant growth inhibition and apoptosis only in high
TLR3-expressing SK-N-AS cells, but not in low TLR3-expressing SK-N-FI and SK-N-DZ cells. Moreover, poly(I:C)
treatment significantly stimulated the activities of PKR, interferon regulatory factor 3 (IRF-3) and caspase-3 in SK-N-
AS cells. Application of TLR3 neutralizing antibody or small interference RNA (siRNA) reduced the poly(I:C)-induced
inhibition of cell proliferation and apoptosis in SK-N-AS cells. On the contrary, ectopic TLR3 expression enhanced
the sensitivity of low TLR3-expressing NB cells to poly(I:C). Finally, application of 2-AP attenuated the poly(I:C)-
induced IRF-3 and caspase-3 activation in SK-N-AS cells.
Conclusion: The present study demonstrates that TLR3 is expressed in a subset of NB cells. Besides, TLR3/PKR/IRF-
3/capase-3 pathway is implicated in the selective cytotoxicity of TLR3 agonist towards high TLR3-expressing NB
cells.
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Introduction
Neuroblastoma (NB) accounts for more than 7% of
malignancies in patients younger than 15 years old and
15% of all pediatric oncology deaths in the United States
[1]. The disease is characterized by its broad range of
clinical manifestations and versatile biological behaviors.
Outcome of the patients with NB is poor for those with
high-risk clinical phenotypes. Based on the latest report
of the Italian Neuroblastoma Registry consisting of 781
NB children, the ten-year overall survival was 6.8% after
progression and 14.4% after relapse [2]. A report from
the Taiwan Children Cancer Foundation revealed that
NB accounts for 6% of malignancies in children and the
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to 23% after disease progression [3].
The major factors influencing the survival of NB
patients are age, stage and MYCN proto-oncogene sta-
tus. Genomic MYCN amplification has been the most
consistent genetic aberration associated with poor prog-
nosis in NB [2,4-6]. Decrease of proliferation rate and
induction of differentiation by a MYCN antisense DNA
oligomer in human NB cell line may explain MYCN
functions [7]. Over expression of MYCN transcriptional
targets and low expression of neuronal differentiation
genes predicts relapse and death from NB [8]. The
MYCN oncoprotein was thus proposed as a drug devel-
opment target [9]. However, recent evidence suggests
that clinicopathological parameters, including tumor cell
ploidy, localized disease and stage, may influence the
prognosis of MYCN in NB [6], [10,11]. Two recent
reports indicate that MYCN amplification alone is not
sufficient to predict the outcome of the patients with
NB [12,13]. Therefore, other factors affecting the
response of NB cells to various stimuli may facilitate
novel diagnostic or therapeutic targets for NB.
Toll-like receptors (TLRs) are human counterparts of
Toll receptors in the fruit fly, Drosophila, which are ori-
ginally implicated in the regulation of dorsoventral
polarity, synaptogenesis, and path-finding in motor neu-
ron growth cone [14]. There are 10 functional toll-like
receptors (TLRs) in humans that specifically recognize
pathogen-associated epitopes. While they are best
known as initiators of the innate immune response to
pathogens, TLRs are also expressed in glia and neurons
of the central nervous system (CNS), which may recog-
nize endogenous ligands and participate both in devel-
opment and in responses associated with CNS injury
[15]. Among the 10 functional TLRs, TLR2 are known
to induce neural inflammation and neuronal damage,
while TLR3 and TLR8 are negative regulators of axonal
or neurite growth by inducing neuronal apoptosis
[16-18].
The strategy of manipulating TLRs signaling is under
active investigation for anti-neoplastic application. For
example, stimulation of TLR9 with CpG oligonucleotide
induces apoptosis of glioma and prolongs the survival of
mice with experimental brain tumors [19]. TLR3 activa-
tion by its agonist directly triggers apoptosis in human
breast cancer cells through activation of extrinsic cas-
pases [20]. Moreover, a series of studies confirm the
potential of TLR3 as therapeutic target for hepatoma,
melanoma and clear cell renal carcinoma [21-24]. Syn-
thetic agonists for several TLRs, including TLR3, TLR4,
TLR7, TLR8, and TLR9, have been or are being devel-
oped for cancer treatment [25]. Despite of these studies,
t h er o l eo fT L R 3e x p r e s s i o ni nN Br e m a i n sl a r g e l y
unknown.
In the present study, we investigated TLR3 expression
in human NB specimens to delineate the correlation of
TLR3 expression with tumor differentiation. Subse-
quently, we analyzed TLR3 expression in three human
NB cells and characterized two NB cells with differential
TLR3 status. Finally, as TLR3 recognizes foreign double-
stranded RNA (dsRNA), we treated these NB cells with
TLR3 agonist, polyinosinic-polycytidylic acid (poly(I:C)),
and monitored the difference in cellular proliferation,
apoptosis, and expression profile of TLR3 signaling
pathway.
Materials and methods
Immunohistochemical studies
Fourteen archival neuroblastic tumor specimens consist-
ing of 8 cases of NB, 5 cases of ganglioneuroblastoma
(GNB) and one ganglioneuroma (GN) were retrieved
from the Department of Pathology, Chang Gung Mem-
orial Hospital-Kaohsiung Medical Center (Kaohsiung,
Taiwan). The use of archival tissues was approved by
the institutional Internal Review Board of the hospital.
In each case, well-preserved areas in paraffin-embedded
NB tissues were reviewed and identified by a pathologist
to prepare a tissues microarray of NB patients, which
consisted of six to eight tissue cores (0.6 mm) from
each patient.
Tissue specimens were maintained in formaldehyde-
fixed, paraffin-embedded blocks. Sections stained with
hematoxylin and eosin (H&E) were also reviewed. The
paraffin sections from specimens were deparaffinized,
blocked with 3% hydrogen peroxide for 10 min and sub-
jected to antigen retrieval with microwave in 0.01 M
citrate buffer for 7 min. The slides were then washed
twice with PBS, incubated with TLR3 antibody (1:2000
dilution; Abcam, Cambridge, MA, USA) at room tem-
perature for 30 min, followed by washing with TBST.
Sections were detected with SuperPicTure Polymer
detection kit (Zymed Laboratories, South San Francisco)
for 30 min and developed with DAB chromogen
(DAKO, USA) for 1 min. Sections were counterstained
with Gill’s hematoxylin, dehydrated and mounted with
mounting medium.
The labeling index of TLR3 was calculated in per-
centage by two pathologists for each case. The immu-
noreactivity of TLR3 was graded according to the
staining intensity as weak (1+), moderate (2+) and
strong (3+) staining. Moderate or strong staining
intensity was considered TLR3-positive. The percen-
tages of positive cells were evaluated for neuroblastic
cells and ganglion cells, respectively, in each neuro-
blastic tumor. Positive staining in more than 50%
tumor cells was defined as “TLR3 overexpression” for
either neuroblastic or ganglion cells. Negative was
defined as <10% of area with staining.
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Three human NB cell lines SK-N-AS, SK-N-FI and SK-
N-DZ were purchased from American Type Culture
Collection (Manassas, VA) and cultured with DMEM
containing 10% (v/v) heat-inactivated fetal bovine serum
( F B S ;I n v i t r o g e n ,C a r l s b a d ,C A ) ,L - g l u t a m i n e ,n o n -
essential amino acids (Invitrogen; 10 mM) and antibio-
tic-antimycotic (Invitrogen) in a 5% CO2 humidified
incubator at 37°C. The SK-N-AS cells were subcultured
at 1:10 ratio when the cells grew to 80-90% of conflu-
ence, SK-N-DZ at 1:6 when 70-80% of confluence and
SK-N-FI at 1:4 when 60% of confluence. To evaluate the
effect of TLR3 agonist, the NB cells (seeded at 3 × 10
4
cells/cm
2 in 60-mm dishes) were treated with Poly(I:C)
(Invivogen; San Diego, CA) in DMEM with 10% FBS at
indicated doses for 24 h.
To verify the specificity of cellular response to poly(I:
C), we also treated the NB cells with lipopolyssacharide
(LPS) and CpG. Neuroblastoma cells were seeded in 60-
mm culture dishes at a cell density of 3 × 10
4 cells/cm
2
and treated with 50 μg/ml Poly(I:C) (TLR3, Invivogen),
10 ng/ml LPS (TLR4, Sigma) or 1 μM CpG-ODN2006
(TLR9, InVivoGen) plus 10% FBS for 24 h.
Quantitative RT-PCR (qRT-PCR) analysis
Total RNA was extracted by using TRIzol
® reagent
(Invitrogen, Carlsbad, CA) from the three cell lines.
After quantification, total RNA (2 μg) were used to pro-
duce cDNA by using the high capacity cDNA reverse
transcription kit (ABI, Applied Biosystems, Foster City,
CA) according to the manufacturer’s recommendations.
Expression levels of human TLR3 mRNA were deter-
mined by qRT-PCR using specific primers in PCR mas-
ter mix (Yeastern Biotechnology; Taipei, Taiwan). The
b-actin level was used as an internal control for normal-
ization of TLR3 mRNA expression using the Prism 7700
Sequence Detection System (ABI). The primer
sequences for qRT-PCR analysis of TLR3 and b-actin
were: TLR3 forward 5’- TGGTTGGGCCACCTA
GAAGT-3’ and reverse, 5’- CCATTCCTGGCCTGT
GAGTT -3’; b-actin forward 5’-TCACCCACACT
GTGCCCATCTACGA-3’ and 5’-CAGCGGAACCGCT
CATTGCCAATGG-3’. The product size for TLR3 was
71 bp and for b-actin was 294 bp.
Cell proliferation assay
Cells were seeded at a density of 5 × 10
3 cells/100 μLi n
96-well plates and cultured overnight. The medium was
changed, and the cells were then cultured in medium
alone (control) or in medium containing different con-
centrations of poly(I:C). After treatment, 10 μL WST-1
reagent (Roche Diagnostics, Laval, Quebec, Canada) was
added to each well and incubated for another 2 h at 37°
C. The absorbance was determined using a microplate
reader at a test wavelength of 450 nm and reference
wavelength of 630 nm.
Flow cytometry analysis
The percentage of cells in G0/G1, S, and G2/M phases
was determined by flow cytometry analysis following
propidium iodide (PI; Sigma, St. Louis, MS) staining.
For PI staining, NB cells were seeded at a concentration
of 1 × 10
6 cells/well in 3 ml medium containing 10%
FBS in 6-well plates and left untreated or treated for 24
h or 48 h with poly(I:C). Cells were washed once with
PBS and then fixed with ice-cold 70% PBS-ethanol for
overnight at -20°C. Fixed cells were washed once with
PBS and incubated in 1 ml PBS containing 10% Triton
X-100, PI (20 mg/ml) and RNase A (Boehringer Man-
nheim, Indianapolis, IN) for 30 min at room tempera-
ture. Samples were analyzed using a FACS (BD
Biosciences) and winMDI software.
Western blot analysis
After treatment, cells were lysed with protein extraction
solution containing proteases inhibitors (iNtRON Bio-
technology) and the protein concentrations were mea-
sured with the BCA assay (Bio-Rad) with bovine serum
albumin as standard. Thirty μg crude proteins were
separated in 12-15% SDS-PAGE gels and transferred to
nitrocellulose membrane. The membranes were immu-
noblotted overnight at 4°C with each primary antibody
at indicated dilution. The primary antibodies included
IRF-3 antibody (Epitomic, Inc.; Burlingame, CA), phos-
phor-IRF3 (pS386) antibody (Epitomic, Inc.), PKR anti-
body (Epitomic, Inc.), phosphor-PKR (pT451) antibody
(Epitomic, Inc.), caspase-3 antibody (Cell Signaling
Technology), and cleaved caspase-3 (Asp175) antibody
(Cell Signaling Technology). Membranes were washed
three times, and subjected to HRP-conjugated secondary
antibody for 60 min at room temperature. Protein-anti-
body complexes were visualized with an ECL Western
blotting detection and analysis system (Amersham Phar-
macia Biotech, Uppsala, Sweden) and blots were
exposed to film. Signals were quantified by densito-
metric analysis.
TUNEL staining
TUNEL (terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate (dUTP) nick end labeling)
assay was used to detect fragmented DNA in SK-N-AS
cells after Poly(I:C) treatment. Cells were grown in 12
well culture plate containing round glass cover slide. 24
h after treatment with Poly(I:C), the cells were fixed for
10 min at room temperature with 4% paraformaldehyde
solution, washed three times with PBS. The TUNEL
assay was performed according to the instruction man-
ual of the In Situ Cell Death Detection Kit (Roche
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mixture for 60 min at 37°C, protected from light,
washed gently three times with PBS, and stained with
DAPI for 5 min at room temperature in a dark cham-
ber. After washing three times with PBS, cells were cov-
ered with cover slips. Photomicrographs were taken
using a fluorescence Microscopy.
TLR3 gene delivery
To increase the cellular TLR3 levels, SK-N-FI and SK-
N-DZ NB cells were transfected with the mammalian
expression vector encoding human TLR3 cDNA fused
with hemagglutinin (HA) tag (OriGene Technologies
Inc.; Rockville, MD) by Lipofectamine 2000 (Invitrogen;
Carlsbad, CA).
TLR3 RNA interference and antibodies neutralization
To knockdown endogenous TLR3 expression, human
TLR3 stealth siRNA and control (scramble) siRNA were
purchased from Invitrogen (Carlsbad, CA). The
sequence for human TLR3 siRNA and control siRNA
was 5’-CCTGAGCTGTCAAGCCACTACCTTT-3’ and
5’-CCTGTCGAACTACCGCATCCAGTTT-3’,r e s p e c -
tively. Gene delivery of siRNA into NB cells was per-
formed using Lipofectamine RNAiMAX (Invitrogen)
following the manufacturer’s protocol. After transfec-
tion, the cells were incubated with poly(I:C) 50 μg/ml
for an additional 48 h before subsequent analysis.
For TLR3 antibody neutralization, NB cells (a density of
8×1 0
4 cells/ml in a 96-well plate) were incubated with
TLR3 antibody (Santa Cruz Biotechnology; Santa Cruz,
CA) at indicated concentrations for 1 h then treated with
50 μg/ml poly(I:C) for 24 h before subsequent analysis.
Statistical analysis
All the data present in the figures were representation of
at least triplicate experiments. Data were expressed as
mean ± SD. Student’s t-test was used for between-group
comparison while analysis of variance was applied when
more than 2 groups were compared. Statistical analysis
of histological findings between different NB groups was
performed using Fisher’s extract test. A P-value less
than 0.05 was considered statistically significant.
Results
TLR3 is expressed in the ganglion cells and differentiated
neuroblastic cells in human neuroblastic tumors
To investigate TLR3 expression in human neuroblastic
tumors, immunohistochemical analysis was performed
using the archival specimens from 14 NB patients con-
sisting of 8 cases of NB, 5 cases of ganglioneuroblas-
toma (GNB) and 1 case of ganglioneuroma (GN). Strong
cytoplasmic TLR3 staining was observed in more than
50% of the ganglion cells in one GN and all GNB
specimens (Figure 1A &1B). There was significant differ-
ence in TLR3 expression between GNB and NB tissues
(Table 1). Interestingly, the TLR3-positive neuroblastic
cells were mainly the differentiated NB cells with some
characteristics of mature cells including nuclear enlarge-
ment, distinct cytoplasmic border, and cell processes, as
well as presence of ganglion cells in sporadic sections
(Figure 1C). However, TLR3 immunostaining was rarely
detectable in the undifferentiated NB cells with charac-
teristics of small, round, blue and dense nests of cells
(Figure 1D). No TLR3 expression was detected in the
stromal cells. The findings suggest the involvement of
TLR3 in the tumorigenesis of NB and provide a ratio-
nale to target TLR3 with TLR3 agonists in vitro.
TLR3 is highly expressed in human SK-N-AS neuroblastic
cells
Since TLR3 differentially expressed in human NB tis-
sues, we examined TLR3 expression in the three human
NB cell lines including SK-N-AS, SK-N-FI and SK-N-
DZ cells. Quantitative RT-PCR showed that the TLR3
mRNA level was significantly higher in SK-N-AS cells
than in the other NB cell lines (Figure 2A). Immunoblot
analysis also revealed a higher TLR3 protein level in SK-
N-AS cells than other two NB cells (Figure 2B). Thus,
TLR3 is differentially expressed in human NB cell lines.
TLR3 agonist preferentially induced growth inhibition and
apoptosis in high TLR-3-expressing NB cells
We subsequently examined whether the endogenous
TLR3 status influenced the cellular response to TLR3 ago-
nist, poly(I:C). By using WST-1 proliferation assay, it was
observed that poly(I:C) treatment significantly inhibited
the proliferation of high TLR3-expressing SK-N-AS cells
in a dose-dependent manner (Figure 3A). In contrast, add-
ing poly(I:C) had discernible effect on the proliferation of
low TLR3-expressing SK-N-FI and SK-N-DZ cells.
We employed flow cytometry analysis to evaluate the
apoptotic extent and cell cycle distribution in poly(I:C)-
treated NB cells. It was found that poly(I:C) treatment
significantly increased the percentages of cells in pre-G0
phase in SK-N-AS cells after treatment for 24 hours (Fig-
ure 3B). The poly(I:C)-induced apoptosis of SK-N-AS
cells was also validated by TUNEL assay (Additional file
1, figure S1). However, poly(I:C) treatment had no signifi-
cant effect on cell proliferation or apoptosis in SK-N-FI
and SK-N-DZ cells even after extended exposure for 48
hours (Figure 3B). Thus, TLR3 agonist preferentially
inhibited the growth of high TLR3-expressing NB cells.
TLR3 agonist stimulated the PKR/IRF-3/caspase-3 pathway
in high TLR3-expressing NB cells
Since PKR is essential for dsRNA signaling, we evaluated
whether poly(I:C) also caused changes in PKR protein
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shown that poly(I:C) treatment significantly enhanced
the phosphorylation of PKR in SK-N-AS cells by more
than 2-fold of control (Figure 4). On the contrary,
neither PKR expression nor phosphorylation in SK-N-FI
Figure 1 TLR3 immunostaining in human neuroblastic tumors. (A) TLR3 expression in ganglioneuroma (GN) and (B) in
ganglioneuroblastoma (GNB). More than 50% of the ganglion cells (asterisk) and some neuroblastic cells (arrow) in GNB tissues exhibited
prominent TLR3 staining. (C) TLR3 expression in differentiated NB tissues. Some neuroblastic (arrow) cells and sporadic ganglion cells (asterisk)
exhibited TLR3 staining. (D) TLR3 expression in the undifferentiated NB tissues. Very few neuroblastic cells were positive for TLR3 expression.
Original magnification, 200×.
Table 1 Immunohisochemical analysis of TLR3 expression
in human neuroblastoma tissues
TLR 3 expression
Low
expression
a
High
expression
b
P
value*
Neuroblastoma (n = 8) 8 (100%) 0 0.002
Ganglioneuroblastoma (n
=4 )
0 4 (100%)
aLow expression: the percentages of TLR3-positive cells less than 30% of total
neuronal cells at low power field.
bHigh expression: the percentages of TLR3-
positive cells ≧ 30% of total neuronal cells at low power field. *Analyzed with
Fisher’s exact probability test
Figure 2 TLR3 expression in human NB cell lines.( A )
Quantitative RT-PCR analysis of TLR3 mRNA level in three NB cell
lines. (B) Western blot analysis of TLR3 protein level in three NB cell
lines. Top panel, immunoblot analysis of TLR3 expression in three
NB cell lines. Bottom panel, quantification results of TLR3 protein
level were mean ± SD of triplicate experiments. **: P < 0.01.
Chuang et al. Journal of Biomedical Science 2011, 18:65
http://www.jbiomedsci.com/content/18/1/65
Page 5 of 13and SK-N-DZ cells was affected by TLR3 agonist. Thus,
TLR3 agonist induced activation of PKR signaling in NB
cells with high TLR3 levels.
Interferon regulatory factor 3 (IRF-3) is known to
undergo phosphorylation-induced activation in virus-
infected cells and plays an important role in the antiviral
innate immune response under the regulation of PKR
[26]. It was found that application of poly(I:C) signifi-
cantly elevated the phosphorylation of IRF-3 in SK-N-
AS cells (data not shown). Interestingly, poly(I:C) treat-
ment also elicited a moderate, yet significant elevation
of phosphorylated IRF-3 in SK-N-FI cells, but not in
SK-N-DZ cells.
Since dsRNA induces cell death through activation of
caspases, we measured the level of procaspase-3 and
active caspase-3 in NB cells after poly(I:C) treatment.
There was no significant change of procaspase-3 level in
the three NB cells at any time point after poly(I:C)treat-
ment. However, active caspase-3 was significantly up-
regulated in SK-N-AS cells at after treatment for 24
hours (Figure 5). A similar trend was also found in SK-
N-FI, in which poly(I:C) treatment induced milder, yet
significant elevation of active caspase-3. Again, active
caspase-3 was not found in poly(I:C)-treated SK-N-DZ
cells. Therefore, TLR3 agonist induced apoptosis in high
TLR3-expressing SK-N-AS cells via caspase-3 activation.
To verify the specificity of cellular response to poly(I:
C), NB cells were also challenged with other TLR ago-
nists, including LPS and CpG, then examined for cap-
sase-3 activation. However, LPS and CpG treatment
failed to elicit caspase-3 activation in all the three NB
cells (Additional file 2, figure S2)
Blockade of TLR3 signaling using neutralizing antibody or
small interference RNA (siRNA) attenuated the poly(I:C)-
induced growth inhibition and apoptosis in SK-N-AS cells
To confirm TLR3 is directly involved in the poly(I:C)-
induced apoptosis, we employed TLR3 neutralizing
Figure 3 Effect of TLR3 agonist on the proliferation and apoptosis of NB cell lines. (A) Cell proliferation assay. After treatment with
different doses of poly(I:C) for 24 h, the proliferation of various NB cells was measured by WST-1 assay and expressed as mean ± SD absorbance
values of quadruplicate experiments. (B) Apoptosis assay. After treatment with 50 μg/ml poly(I:C) for 24 h, the apoptosis of various NB cells was
determined by flow cytometry analysis following propidium iodide staining and expressed as mean ± SD percentages in pre-G0 stage from
triplicate experiments. *: P < 0.05.
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cells. It was found that caspase-3 activation was signifi-
cantly perturbed by TLR3 antibodies blockade (Figure
6A), but not by non-specific antibody (Additional file 3,
figure S3). Flow cytometry analysis further revealed that
TLR3 antibody neutralization significantly reversed the
poly(I:C)-induced apoptosis in SK-N-AS cells (Figure
6B). By cell proliferation assay, it was found that prior
incubation with TLR3 antibody significantly increased
the proliferation of SK-N-AS cells, thereby perturbing
the growth inhibition mediated by poly(I:C) treatment
(Figure 6C).
To further validate the role of TLR3 in poly(I:C)-
induced apoptosis, SK-N-AS cells were transfected with
TLR3-specific small interference RNA (TLR3 siRNA)
then monitored for cellular responses to poly(I:C). It
was found that gene delivery of TLR3 siRNA, but not
control siRNA, led to significant reduction (more than
50%) of TLR3 mRNA level (Additional file 4, figure S4).
Besides, TLR3 knockdown significantly reversed the poly
(I:C)-induced caspase-3 activation, apoptosis and growth
inhibition in SK-N-AS cells (Figure 7). Together, these
results supported the pro-apoptotic and anti-prolifera-
tive function of TLR3 signaling in human NB cells.
Ectopic TLR3 expression rendered the low TLR3-
expressing NB cells sensitive to poly(I:C) treatment
Subsequently, we examined the feasibility of sensitizing
the low TLR3-expressing NB cells to poly(I:C) by ecto-
pic TLR3 overexpression. After transfection with TLR-
3-expressing vector, it was observed that TLR3 gene
delivery significantly elevated the HA-positive, exogen-
ous TLR3 level in SK-N-FI and SK-N-DZ cells (Figure
8A). Despite the lack of effect on apoptosis and cell pro-
liferation by itself, transient TLR3 expression signifi-
cantly augmented the poly(I:C)-mediated apoptosis and
growth inhibition in both low TLR3-expressing cells.
This also seemed in accordance with the reduction of
TLR3 transgene level in NB cells upon simultaneous
poly(I:C) application. Thus, ectopic TLR3 expression
indeed sensitized the low TLR3-expressing NB cells to
poly(I:C) treatment.
Pharmaceutical inhibition of dsRNA-regulated protein
kinase (PKR) attenuated poly(I:C)-induced action of PKR/
IRF3/caspase 3 pathway
To determine the role of dsRNA-regulated protein
kinase (PKR) in TLR3-mediated cell death, SK-N-AS
cells were treated with PKR inhibitor, 2-aminopurine (2-
AP), followed by poly(I:C) administration. 2-AP signifi-
cantly blocked the expression of p-PKR (Additional file
5, figure S5), reduced the expression of p-IRF3 (Addi-
tional file 5, figure S5B) from 3 h up till 24 h after treat-
ment, resulting in significant reduction of activated
caspase-3 expression at 24 h in SK-N-AS (Additional
file 5, figure S5C).
Discussion
The first report that TLR3 can directly trigger apoptosis
in human breast cancer cells opened a new avenue for
cancer therapeutics [20]. The observation quickly gained
Figure 4 Effect of TLR3 agonist on PKR expression and
phosphorylation in NB cell lines. (A) Western blot analysis. After
treatment with 50 μg/ml poly(I:C) for 24 h, NB cells were harvested
and subjected to immunoblot analysis. (B) Quantification of PKR
activation in NB cells after poly(I:C) treatment. The ratio of
phosphorylated PKR level over total PKR level was determined and
expressed as mean ± SD from triplicate experiments. *: P < 0.05.
Figure 5 Effect of TLR3 agonist on caspase-3 activation in NB
cell lines. (A) Western blot analysis. After treatment with 50 μg/ml
poly(I:C) for 24 h, NB cells were harvested and subjected to
immunoblot analysis. (B) Quantification of active caspase-3 in NB
cells after poly(I:C) treatment. The ratio of active caspase-3 over
procaspase-3 level was determined and expressed as mean ± SD
from triplicate experiments. **: P < 0.01. *: P < 0.05.
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in the tumorigenesis of hepatoma, melanoma and clear
cell renal carcinoma [21-24]. In this study, we provided
the first evidence that TLR3 is differentially expressed in
human NB tissues and cells. The histological study in
human NB tissues reveals that TLR3 expression is pre-
sent mainly in the cytoplasm of ganglion cells of GNB,
but rare or not detectable in the neuroblastic cells of
NB. Besides, TLR3 is not present in the stromal cells.
These findings indicate heterogeneous neuroblastic cell
types in human neuroblastic tumors that harbor differ-
ential TLR3 levels and may respond differently to TLR3
agonist.
Histological studies revealed that TLR3 expresses
mainly in the cytoplasm of ganglion cells in GNB tis-
sues. In contrast, TLR3 was rarely detected in
neuroblastic cells of NB tissues. There is an excellent
correlation between differentiation and apoptosis in NB
tissues. Hoehner et al. found that the most differentiated
NB cells lie adjacent to TUNEL-positive, morphologi-
cally apoptotic cells [27]. Another study also showed
that apoptosis in neuroblastic tumor is present mainly
in cases with well differentiation status and favorable
outcome [27]. The above findings implicate that the
interplay between differentiation and apoptosis may be
involved in the regression of neuroblastic tumors [27].
Our findings of TLR3 expression in the more differen-
tiated NB tissues and TLR3 signaling during apoptosis
of NB cell lines seem consistent with the above notions.
However, due to the relative small sample size in this
study, future studies are warranted to validate the role
of TLR3 signaling in differentiation and apoptosis in NB.
Figure 6 Effect of TLR3 neutralization on poly(I:C)-induced apoptosis in SK-N-AS cells. (A) Effect of TLR3 neutralization on poly(I:C)-induced
caspase-3 activation. After incubation with TLR3 antibodies of indicated doses for 1 h, SK-N-AS cells were treated with poly(I:C) (50 μg/ml) for 24
h, and then harvested for immunoblot analysis (top panel). Arrows indicated the molecular weight of active caspase-3 at 17 kDa and 19 kDa,
respectively. Quantification results of caspase-3 activation in different treatment groups were expressed as mean ± SD from triplicate
experiments (bottom panel). #: P < 0.05 versus non-treated control, **: P < 0.01. (B) Flow cytometry analysis of poly(I:C)-induced apoptosis in SK-
N-AS cells after TLR3 neutralization. Data were mean ± SD from triplicate experiments. #: P < 0.05 versus non-control, *: P < 0.05. (C) Cell
proliferation assay of poly(I:C)-induced growth inhibition in SK-N-AS cells after TLR3 neutralization. Data were mean ± SD from quadruplicate
experiments. #: P < 0.05 versus non-control, *: P < 0.05.
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matory signaling in TLR3-expressing astrocytes
through activation of PKR [28]. PKR is also the essen-
tial component of TLR3-mediated NF-B activation in
human epidermal keratinocytes [29]. Another study
also reported that PKR was required for maximal type
I IFN-beta induction and the induction of apoptosis in
different cell lines by both transfected T7 phage poly-
merase-synthesized RNA and Poly(I:C) [30]. In cul-
tured human biliary epithelial cells, stimulation with
poly(I:C) induces the activation of both transcription
factors NF-B and IRF3 and the production of inter-
feron-beta1 (IFN-beta1) and MxA as potent antiviral
responses [31]. The above studies are consistent with
our studies in NB cells, indicating that TLR3/PKR/
IRF3 signaling components are not only for innate
immune response against viral infection, and probably
respond to tumor antigens, in various human cell lines
including NB cells.
It remains elusive how TLR3 executes its function
upon ligand stimulation in NB cells. TLR3 is known to
be localized in the endoplasmic reticulum (ER) of
unstimulated cells [32,33]. In response to ligand stimu-
lation, TLR3 may move to endosomes or other com-
partments to execute antiviral activities or
inflammatory cytokine production [34]. Two ER pro-
teins, glucose-regulated protein 78 (GRP78) and calre-
ticulin, have been identified as independent prognostic
factors for NB patients [35,36]. Our pilot study
revealed that poly(I:C) induced significant upregulation
of GRP78 and calreticulin in SK-N-AS cells, but not in
SK-N-FI and SK-N-DZ (Chuang et al.; unpublished
observation). Thus, TLR3 signaling may affect the
expression of some ER proteins and control the cell
Figure 7 Effect of TLR3 knock-down on poly(I:C)-induced apoptosis in SK-N-AS cells. After transfection with siRNA (60 nM) for 24 h, the
cells were incubated with poly(I:C) 50 μg/ml or vehicle for another 24 h and were then harvested for assay. C, control; LI, lipofectamine; SC.
Scramble control siRNA; siTLR3, TLR3 siRNA. (A) Effect of TLR3 siRNA knockdown on poly(I:C)-induced caspase-3 activation. Arrows indicated the
molecular weight of active caspase-3 at 17 and 19 kDa, respectively. Quantification results of caspase-3 activation in different treatment groups
were expressed as mean ± SD from triplicate experiments (bottom panel). *: P < 0.05, **: P < 0.01. (B) Flow cytometry analysis of poly(I:C)-
induced apoptosis in SK-N-AS cells after TLR3 siRNA knockdown. Data were mean ± SD from triplicate experiments. **: P < 0.01. (C) Cell
proliferation assay of poly(I:C)-induced growth inhibition in SK-N-AS cells after siRNA knock-down of TLR3. Data were mean ± SD from triplicate
experiments. *: P < 0.05.
Chuang et al. Journal of Biomedical Science 2011, 18:65
http://www.jbiomedsci.com/content/18/1/65
Page 9 of 13fate or differentiation of high TLR3-expressing NB
cells. An interesting observation reveals the association
of TLRs with other ER membrane proteins such as
UNC93B. Single point mutation (H412R) in UNC93B
abolishes signaling via TLR3, 7, and 9 [37]. The latter
suggests a physical association between UNC93B and
TLRs in the ER is probably essential for proper TLR
signaling in high TLR3-expressing NB cells.
In this study, both TLR3 antibody and siRNA can
attenuate the poly(I:C)-induced inhibition of cell prolif-
eration as well as apoptosis, which was most prominent
in SK-N-AS cells (Figure 9). One interesting finding is
that treatment of NB cells with either TLR3 antibody or
TLR3 siRNA is able to increase cell proliferation in all
the three NB cells. The findings are consistent with pre-
vious reports, which reveal that TLR3 signaling is a
negative regulator of embryonic neural progenitor cell
proliferation or liver regeneration (46, 47). Blockade of
TLR3 signaling may therefore reverse the function and
augment NB cell proliferation.
In summary, the present study unveiled the differential
TLR3 expression in different types of NB specimens.
Moreover, this study demonstrated the susceptibility of
high TLR3-expressing NB cells to agonist-induced apop-
tosis and the involvement of PKR/IRF3/caspase 3 signal-
ing pathways. Further studies with the aid of
pretreatment with interferon alpha [38], simultaneous
administration of CpG DNA [19,39], or targeting
MYCN or MDA5 may be helpful in augmenting the
poly(I:C) sensitivity and NB immunotherapy. As an
intracytoplasmic RNA sensor, MDA5 expression was
higher in SK-N-FI (unpublished data), which also
responded to poly(I:C) treatment and might explain why
active caspase-3 expression was higher in SK-N-FI than
Figure 8 Effect of ectopic TLR3 overexpression on the poly(I:C) sensitivity in low TLR3-expressing NB cells. (A, B top panel) Immunoblot
analysis of endogenous and exogenous TLR3 expression in transfected SK-N-FI and SK-N-DZ cells in the absence or presence of a 24-h poly(I:C)
treatment. C: control, V: vector, TLR3: TLR3-expressing vector. (A, B middle panel) Flow cytometry analysis of apoptotic response in TLR3-
transduced SK-N-FI and SK-N-DZ cells in the absence or presence of poly(I:C) treatment. Data were mean ± SD from triplicate experiments. *: P <
0.05. (A, B bottom panel) Cell proliferation assay of TLR3-transduced SK-N-FI and SK-N-DZ cells in the absence or presence of poly(I:C) treatment.
Data were mean ± SD from quadruplicate experiments *: P < 0.05.
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Page 10 of 13in SK-N-DZ, despite both were lower than that in SK-
N-AS.
Conclusion
This study unveiled that TLR3 is expressed in a subset
of relatively benign NB cells. Besides, TLR agonist
induced proapoptotic activity in NB cells with high
endogenous TLR3 level. Genetic manipulation data
further support that the cellular TLR3 level determined
the sensitivity of NB cells to poly(I:C)-induced cell
death. Our study may open a new avenue of therapeutic
indication for TLR3 agonists as an adjuvant therapy in
intractable NB.
Additional material
Additional file 1: Figure S1. TUNEL (terminal deoxynucleotidyl
transferase-mediated deoxyuridine triphosphate (dUTP) nick end labeling)
assay was used to detect fragmented DNA in SK-N-AS cells 24 h after
poly(I:C) treatment. DAPI was used for staining of the nucleus. Positive
immunostaing was present only in some NB cells after Poly(I:C)
treatment, but not in control.
Additional file 2: Figure S2. Effect of TLR agonists on caspase-3
activation in NB cells. NB cells were treated with TLR agonists including
TLR3 agonist (Poly(I:C); 50 μg/ml), TLR4 agonist (LPS; 10 ng/ml), and TLR9
agonist (CpG-ODN2006; 1 μM) for 24 h and subjected to immunoblot
analysis of caspase-3 activation.
Additional file 3: Figure S3. Neutralization of TLR3 in SK-N-AS revealed
that TLR3 specific antibody, in comparison with non-specific IgG control,
down-regulated the expression of active caspase-3 expression. However,
for uncertain reason, high dose of IgG may also exert some
neutralization effect.
Additional file 4: Figure S4. Transfection of siRNA targeting TLR3 or
scramble RNA was evaluated by using QRT-PCR to detect TLR3 mRNA.
TLR3 mRNA expression decreased to 43% in SK-N-AS cells treated with
siRNA targeting TLR3 (siTLR3), but not in scramble or lipofectamine
control.
Additional file 5: Figure S5. Effect of PKR inhibitor, 2-aminopurine (2-AP),
on poly(I:C)-induced suppression of PKR and IRF3 expression and
caspase-3 activation in SK-N-AS cells. (A) NB cells were pretreated with 2-
AP (10 mM) for 5 min, followed by treatment with 50 μg/ml poly(I:C) for
24 h, then harvested for immunoblot analysis. (A) Immunoblot analysis of
total and phosphorylated PKR (top panel). Quantification of PKR
activation was determined using phosphorylated PKR/total PKR (bottom
panel). Data were mean ± SD from triplicate experiments. *: P < 0.05. **:
P < 0.01. (B) Immunoblot analysis of total and phosphorylated IRF-3 (top
panel). Quantification of IRF3 activation was determined using
phosphorylated IRF3/total IRF3 (bottom panel). Data were mean ± SD
Figure 9 Scheme for poly(I:C)-induced apoptotic signaling pathway in high TLR3-expressing NB cells (left panel), but not low TLR3-
expressing NB cells (right panel).
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Page 11 of 13from triplicate experiments. **: P < 0.01. (C) Immunoblot analysis of pro-
and activated caspase-3 (top panel). Quantification of caspase 3
activation was determined using activated caspase-3 level over
procaspase-3 level (bottom panel). Data were mean ± SD from triplicate
experiments. **: P < 0.01.
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